“Dr. Paul has been fantastic. A few years back i had an emergency and he was very calm and helped me thru the process. I couldn't ask for a better ophthalmologist!”
Why Does My Insurance Require Me to Try Avastin First?
The Drugs Your Plan Is Comparing
All of the medications your plan is weighing belong to the same class, called anti-VEGF therapy. VEGF stands for vascular endothelial growth factor, a signal that causes abnormal, leaky blood vessels to grow under or within the retina. These drugs block that signal. Their differences involve approval history, packaging, and price more than how they work.
Avastin was originally developed and approved as a cancer treatment given intravenously. Retina specialists use a very small fraction of a vial, injected directly into the eye, which is a use that does not appear on the FDA-approved label. This is called off-label use.
Off-label use is legal, common in medicine, and does not mean the drug is unproven for your purpose. Large randomized clinical trials have tested bevacizumab in the eye head-to-head against the eye-specific alternatives, and those results are reviewed below.
Lucentis (ranibizumab), Eylea (aflibercept), and Vabysmo (faricimab) were each developed and tested specifically for eye disease and carry FDA approval for retinal indications. They are packaged as single-eye doses, which means no outside pharmacy needs to divide a vial before use. That packaging difference is one honest advantage of these products over Avastin.
You may also hear about biosimilars, which are closely related copies of Lucentis or Eylea made by different manufacturers, and about higher-dose or longer-lasting formulations of existing drugs. Insurance preferred lists are updated each year, and the product your plan designates as preferred may not be the same from one year to the next. It is worth confirming with your plan which product it currently prefers.
The clinical evidence supporting bevacizumab in the eye has accumulated over many years, and the price gap between it and the approved alternatives has never closed. Anti-VEGF injection is established as the first-line treatment for wet age-related macular degeneration (AMD), and treatment guidelines indicate that the choice of product should rest with the treating physician and patient wherever possible. Many retina specialists reach for Avastin first when the evidence supports it and the clinical picture fits.
What the Clinical Research Shows
Several large, well-designed trials have compared these drugs directly. The results are specific to diagnosis and starting vision level, so understanding which group you fall into matters when discussing options with your retina specialist.
The Comparison of AMD Treatments Trial (CATT) enrolled over 1,100 people with wet AMD and compared bevacizumab with ranibizumab given on the same schedule. The two drugs produced equivalent vision results at one and two years. A review of national clinical practice guidelines reached the same practical conclusion, finding no clinically significant difference in effectiveness or safety among the main anti-VEGF options for wet AMD. For this diagnosis, starting with Avastin is considered clinically reasonable.
Diabetic macular edema (DME) is swelling in the central retina caused by diabetes. In Protocol T, a large trial comparing all three main anti-VEGF drugs in people with DME, patients whose starting vision was roughly 20/32 to 20/40 gained similar amounts of vision on all three medications. For this group, the choice of drug made little measurable difference at one year.
The picture shifts when starting vision has already dropped further. In Protocol T, eyes starting at 20/50 or worse gained approximately 18.9 letters with aflibercept compared to approximately 11.8 letters with bevacizumab at one year. That difference is roughly one and a half lines of vision. If your starting vision falls in this range, that result is a concrete, evidence-based reason to discuss requesting an exception before treatment begins.
Protocol AC directly tested the step therapy strategy in eyes with diabetic macular edema. One group started on bevacizumab and switched to aflibercept if the response was insufficient. The other group received aflibercept from the start. After two years, vision gains were similar between the two groups, approximately 14 letters versus 15 letters, a difference that was not statistically significant. The two-year cost for the bevacizumab-first group was roughly half that of the aflibercept group.
One important detail from that trial is that about 70 out of every 100 eyes in the bevacizumab-first group were eventually switched to aflibercept. The strategy worked because switching happened when it was needed, not because bevacizumab alone carried every eye to the same outcome.
Risks and Safety Considerations
Every anti-VEGF injection carries a shared set of possible side effects, and Avastin has one additional consideration related to how it is prepared. Understanding these helps you ask the right questions before treatment begins.
The most frequent effects after any anti-VEGF injection are a red spot on the white of the eye, mild soreness, and temporary blurring. These are generally mild and resolve on their own within a day or two.
The rare but serious risk is endophthalmitis, which is an infection inside the eye. In the CATT trial it occurred in approximately 5 of every 1,000 patients treated over the first year. This complication is uncommon and, when caught early, is treatable. Warning signs are listed in a later section of this page.
Because a single vial of Avastin contains far more than one eye needs, a compounding or outsourcing pharmacy divides it into individual syringes before each use. This extra preparation step is the honest downside of the less expensive option. Contaminated batches from repackaging facilities have been linked to documented clusters of eye infection in the past.
The practical response is to ask a direct question: your retina specialist's office should be able to tell you which outsourcing facility supplies their bevacizumab syringes. A well-run practice expects that question and has a ready answer.
In the CATT trial, serious systemic (whole-body) adverse events were reported in slightly more bevacizumab patients than ranibizumab patients, but the authors noted the gap could reflect chance or health differences between the two groups at the start rather than a true drug effect. A later Cochrane review that pooled nine randomized trials with over 3,600 patients found no clear difference in deaths or serious systemic side effects between the two drugs over two years. The larger pooled analysis did not confirm the earlier signal, which is the usual result when a small imbalance turns out to reflect noise rather than a real difference.
Requesting a Step Therapy Exception
If your clinical situation makes the plan's preferred drug a poor choice for your eye, the exception process is the correct path forward. Your retina specialist plays a central role in this process, and knowing what a strong request includes helps move things along efficiently.
You can file an exception request, and your retina specialist can file one on your behalf. For Medicare Advantage plans, the option to request an exception is required by regulation. For commercial plans, the process goes by different names, such as prior authorization override or medical necessity review. Call the member services number on your insurance card, ask for the specific form name and submission instructions, and then bring that information to your retina specialist's office.
Vague statements of clinical preference are the most common reason exception requests come back denied. A well-documented request is specific and tied directly to your case.
- Your diagnosis and your current best-corrected vision in the affected eye, expressed as a letter score or a standard measurement such as 20/50.
- A specific clinical reason the preferred drug is a poor fit, such as diabetic macular edema with starting vision of 20/50 or worse, a documented prior non-response to the preferred drug, or a prior adverse reaction.
- The name of the trial supporting the request, such as Protocol T for the lower-starting-vision diabetic group.
- A plain-language statement of what continued delay is likely to do to the eye.
Insurance plans operate on defined decision timelines, not open-ended ones. Standard requests are generally decided within a few days. If your retina specialist certifies that waiting for a decision could seriously harm your health, an expedited review is available and moves faster. Write down the date you submitted the request, the confirmation or reference number, and the name of whoever you spoke with at the plan. If the deadline passes without a decision, that record is what allows you to escalate.
A denial is not the end of the process. The written notice must explain your appeal rights, and you have the right to use them. Ask your retina specialist to request a peer-to-peer review, where they speak directly with the plan's physician reviewer. Ask for the plan's coverage criteria in writing. Ask whether the drug manufacturer offers a patient assistance program. In the meantime, keep receiving the covered drug on schedule. Being treated with your second-choice medication is far better than going without treatment while paperwork is pending.
Warning Signs and Keeping Treatment on Track
Injection visits are routine for most patients, but there are symptoms that require the same-day attention of a retina specialist. Knowing these in advance means you will act quickly if one appears, which is what determines how well a complication can be managed.
These symptoms are uncommon. Memorizing them now means you will not have to search for information when it matters most.
- Severe eye pain that builds over hours instead of easing after an injection.
- Sudden vision loss, or vision that worsens rather than stabilizes a day or two after treatment.
- Increasing redness with discharge, or a swollen lid that is difficult to open.
- A shower of new floaters, flashing lights, or a dark curtain moving across your field of vision.
If any of these appear, call your retina specialist's office immediately, including evenings and weekends. Use the emergency room if you cannot reach anyone. Both endophthalmitis and retinal detachment are treatable conditions, and outcomes are generally better the sooner care begins.
A delayed refill on an oral medication often means a few missed doses. A delayed eye injection means weeks of continued leaking or swelling under the retina, and vision lost to prolonged swelling does not always return. If your paperwork has stalled for more than a week, call the retina office and say plainly that you are concerned about a treatment gap. Many practices can keep you on the covered drug during an active appeal so your treatment schedule does not fall behind.
Keep every scheduled visit even when the drug question is unresolved. The imaging scans taken during that period show exactly what any delay is doing to your retina, and that record often becomes the strongest supporting evidence in an appeal. Bringing a personal log of your injection dates, which drug was used, and how your vision felt afterward is also a useful habit that your care team will appreciate.
Frequently Asked Questions
The questions below address situations and decisions that do not fit neatly into the sections above. Each answer is meant to help you decide what to do next, not to repeat what is already covered.
Your plan is deciding what it will pay for, not what may legally or medically be used in your eye. Your retina specialist retains the authority to recommend any treatment and to formally request that the plan cover a different drug when there is clinical justification. The exception process exists precisely because the plan's payment decision and your doctor's clinical judgment do not always land in the same place. If they conflict, a documented request with your current vision measurement, your diagnosis, and the supporting trial evidence is the right first move, not quiet acceptance of the coverage letter.
The two-year data from Protocol AC does not support that concern for the groups studied. Eyes that started on bevacizumab and switched to aflibercept when the response was insufficient finished at a similar vision level to eyes that had aflibercept from the start. The greater risk to your long-term vision is a gap in treatment while an appeal is unresolved, not the order in which the drugs appear. Needing to switch is an expected part of the bevacizumab-first strategy, not a sign that something went wrong.
In Medicare Advantage, generally no. The step therapy rule applies when starting a new medication, and the regulation that permits this policy also specifies that a patient already receiving a Part B drug cannot be required to change to the plan's preferred product. Commercial insurance plans vary more on this point, so ask your insurer specifically about continuity of care or grandfathering language when your plan renews each year. If a switch letter arrives while you are responding well to your current treatment, contact your retina specialist before agreeing to anything and ask them to document your current response in writing.
The price difference reflects development history and market positioning, not manufacturing difficulty. Eylea and Lucentis were researched, trialed, and approved specifically as eye drugs, and they are sold at eye-drug prices. Avastin is sold as a cancer drug, and a single vial intended for intravenous cancer use is divided into many small eye doses, which distributes the cost very thinly. From a patient cost-sharing perspective, this matters: under Medicare Part B, you generally pay a percentage of the allowed amount, so a more expensive drug often means a larger out-of-pocket bill for you personally, even if your plan is covering the rest.
Your retina specialist does not rely on symptoms alone. At each visit, an imaging scan called OCT (optical coherence tomography) measures the thickness and fluid level in your retina with precision. Your letter score on the vision chart is also recorded at every appointment. Fluid that stops decreasing, retinal thickness that increases between visits, or a declining letter score are the objective signals that prompt a change in approach. Ask to see your OCT images side by side across visits. The trend line is more informative than any single number, and seeing it yourself makes the decision about switching much easier to understand.
Preparing a short written list before your appointment leads to much more useful conversations than trying to remember questions in the moment. Consider asking which specific drug your plan currently requires first and how many injections are needed before a different drug can be requested, whether your diagnosis and current vision level give reason to request an exception before starting, which objective scan measurements will be used to judge whether this drug is doing enough, and which outsourcing facility supplies the bevacizumab syringes used in the office. Also ask who in the office handles exception and appeal filings, and what the correct steps are if your vision changes suddenly between visits.
Visit Atlantic Retina Center
At Atlantic Retina Center, our team of fellowship-trained, ABO board-certified retina specialists focuses exclusively on conditions of the retina, vitreous, and macula, bringing the full depth of vitreoretinal expertise to every patient we see across the Eastern Shore of Maryland and central and southern Delaware. If you are navigating an insurance step therapy requirement, have questions about your current treatment, or simply want a specialist opinion on your retinal health, we are here to help you understand your options and get the care your eyes need.